Piramal Pharma Q3 FY26 Results: Revenue Down 3%, PAT at (₹136) Crore
Piramal Pharma reported Q3 FY26 consolidated revenue of ₹2,140 crore (down 3% YoY) and a PAT loss of ₹136 crore. EBITDA fell 32% to ₹239 crore. The company noted signs of recovery in order inflows and is acquiring Kenalog® for up to US$100 million. A conference call is scheduled for January 29, 2026.
The decline in revenue and profitability, along with the net loss, has a notable negative impact on the company's financial standing. However, the mention of recovery signs and strategic acquisitions mitigates a high impact.
The company reported a year-on-year decline in revenue and EBITDA, along with a significant net loss for the quarter and nine-month period, indicating negative financial performance.
Piramal Pharma Limited announced its un-audited financial results for the third quarter (Q3) and nine months (9M) ended December 31, 2025. The company reported consolidated revenue from operations of ₹2,140 crore for Q3 FY26, a 3% decrease compared to ₹2,204 crore in Q3 FY25. For the nine-month period, revenue stood at ₹6,117 crore, down 4% from ₹6,397 crore in the same period last year.
Consolidated EBITDA for Q3 FY26 was ₹239 crore, a 32% decline from ₹350 crore in Q3 FY25. The EBITDA margin compressed to 11% from 16% year-on-year. Profit After Tax (PAT) after exceptional items stood at a loss of ₹136 crore for Q3 FY26, compared to a profit of ₹4 crore in the prior year. For the nine-month period, PAT was a loss of ₹317 crore, versus a loss of ₹62 crore in 9M FY25.
The company cited inventory destocking in a key product, slower early-stage order inflows due to inconsistent recovery in US biopharma funding, and regulatory delays in inhalation anesthesia as reasons for the revenue impact. However, Piramal Pharma noted early signs of recovery with a pickup in Requests for Proposals (RFPs) and order inflows since October 2025, driven by improved biopharma funding and increased M&A activities in the US.
Key business highlights include the acquisition of Kenalog® for an upfront consideration of US$35 million and a contingent consideration of up to US$65 million. The Complex Hospital Generics (CHG) business saw revenue growth of 2% in Q3 FY26, while Piramal Consumer Healthcare (PCH) reported a robust 20% revenue growth, driven by power brands and e-commerce sales.
Piramal Pharma Limited will be hosting a conference call for investors and analysts on January 29, 2026, from 9:30 AM to 10:15 AM IST to discuss its Q3 and 9M FY26 results.
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.